Patients who had radical hysterectomy for stage IB-IIB cervical cancer, and were certified to have lymph node mestastases histologocally after radical surgery. Patients with only squamous cell carcinoma were eligible.
Conditions
Interventions
Concurrent chemoradiotherapy (Group A) Whole pelvic irradiation (50 Gy) and CDDP 70mg/m2, each 4 week, 3 times.
Chemotherapy (Group B) CDDP 70mg/m2, each 4 week, 3 times.
Sponsors
Study Group of Postoperative radiotherapy for cervical cancer.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. squamous cell carcinoma of the cervix and clinical stage IB-IIB. 2. radical hysterectomy was performed. 3. with histologically certified lymph node metastases. 4. no abnormal findings in laboratory tests. 5. PS is between 0-2. 6. Age is between 20-75. 7. No chemotherapy for other cancer (except cervical cancer) within recent 3 months.
Exclusion criteria
Exclusion criteria: 1. Past history of pelvic surgery (except appendectomy). 2. past history of pelvic irradiation. 3. Positive surgical margin, or positive paraaortic lymph nodes. 4. Estimaated survival is less than 6 months. 5. Renal dysfunction. 6. Acitve infection (Tuberculosis or mycosis) in the pelvis. 7. Active double cancer. 8. Otehr reasons that is not eligible to this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrent rata including distant metastases. | — |
Secondary
| Measure | Time frame |
|---|---|
| Late adverse effect Survival | — |
Countries
Japan
Contacts
Public ContactTakahsi Uno, M.D.
Chiba University, Graduate School of Medicine, Department of Radiology
Outcome results
None listed